Hi Marc,
Thoughts on BDX's plans? I looked at the glucose monitor on the CYGN web site, wish I had a better understanding on it's shortcommings; suspect it was something to do with the patch;
cygn.com
I went back to the BJCT web site and pulled the paragraph dealing with the glucose monitoring from the press release;
Said Michael Sember, Elan's vice president of planning, investments and development, who will be appointed to Bioject's Board of Directors: "We look forward to working with a highly innovative company like Bioject that has a proven track record in developing and manufacturing products, meeting FDA standards, and bringing products to market. With Bioject, we can collaborate with a strong U.S.-based partner to bring our glucose monitoring technology successfully to market. In addition, our participation in Bioject's development of needle-free pre-fill technology will give Elan access to a new innovative drug delivery system."
Added Sember: "Based on current market studies, we believe the continuous glucose monitoring system we are developing has tremendous market potential. In contrast to most products in the
marketplace, our ambulatory system will provide a disposable skin patch-like sensor that is patient-friendly, minimally invasive, easy to use - coupled with a lightweight monitoring device. In addition, by providing accurate information on a real-time basis at considerably less effort, our continuous system is likely to foster better monitoring. Better monitoring and glucose management can help patients avoid the worst complications of diabetes. We anticipate that our product will be competitively priced accounting for the enhanced performance it will provide over existing technologies in the marketplace."
Then keep in mind that one of our board members came from CYGN!
Anyone care to speculate?
best, art |
